IN 001 - InnoRNA
Alternative Names: IN-001 InnoRNALatest Information Update: 24 May 2024
At a glance
- Originator InnoRNA
- Class RNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes zoster
Most Recent Events
- 25 Apr 2024 Preclinical trials in Herpes zoster in China (IM) before April 2024
- 25 Apr 2024 InnoRNA (Shenzhen Shenxin Biotechnology) plans a phase I trial for Herpes zoster (Prevention) in China (IM, Injection) in July 2024 (NCT06375512)
- 23 Sep 2023 US FDA approves IND application for IN 001 in Herpes zoster